Skip to main content
Skip to footer
Main menu
Health systems
Investor Relations
Careers
United States
Choose your country
Select to view the solutions available in your location.
France
Deutschland
Italia
日本
Polska
United Kingdom
United States
United States
Login
Track orders, get results, manage your info, and more.
Order tests, track orders, get results, and more.
Products and services
Science
About
News and events
Exact Sciences
Authors
Exact Sciences
Exact Sciences Reinforces International Leadership in Breast Cancer with Strong Presence at 2025 San Antonio Breast Cancer Symposium
Exact Sciences
Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments
Exact Sciences
Exact Sciences Announces Expiration Of The HSR Waiting Period For Exclusive License To Freenome’s Blood-Based Colorectal Cancer Screening Tests
Exact Sciences
Exact Sciences Announces Breakthrough Results from Landmark Study Demonstrating Superior Early Detection of Liver Cancer with Blood-Based Surveillance Test
Exact Sciences
Exact Sciences Announces Third Quarter 2025 Results
Exact Sciences
Exact Sciences Presents New Findings at ACG 2025 Demonstrating How the Cologuard Test Helps Improve Adherence and Close Screening Gaps
Exact Sciences
New Study in Journal of the National Cancer Institute Finds Cologuard Plus™ Provides the Most Life-Years Gained with the Fewest Colonoscopies
Exact Sciences
Horror Icon Matthew Lillard and Exact Sciences Help Adults 45+ Conquer Fear and Get Screened for Colon Cancer with the Cologuard® Test
Exact Sciences
Exact Sciences Launches the Oncodetect™ Molecular Residual Disease Test
Exact Sciences
Exact Sciences Awards Grants to 28 Organizations Focused on Increasing Colorectal Cancer Screening
Exact Sciences
Exact Sciences and Humana Expand Colorectal Cancer Screening Partnership with Cologuard Plus™ Test Cologuard Plus™ Available In-Network August 2025
Exact Sciences
Cologuard Included in American Cancer Society Colorectal Cancer Prevention and Early Detection Guidelines
Exact Sciences
Exact Sciences Launches Cancerguard™, First-of-Its-Kind Multi-Cancer Early Detection Blood Test
Exact Sciences
Exact Sciences Announces Exclusive License with Freenome for Blood-Based Colorectal Cancer Screening tests
Exact Sciences
Exact Sciences Announces Second Quarter 2025 Results
Exact Sciences
Exact Sciences and Humana Expand Colorectal Cancer Screening Partnership with Cologuard Plus™ Test Cologuard Plus ™ Available In-Network August 2025
Exact Sciences
Exact Sciences Announces Medicare Coverage for Oncodetect™ Molecular Residual Disease Test in Colorectal Cancer
Exact Sciences
Exact Sciences Announces Expanded Clinical Validation of the Oncodetect™ Test and Molecular Residual Disease Innovation Roadmap
Exact Sciences
Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025
Exact Sciences
Exact Sciences Earns 2025 Great Place To Work® Certification™
Exact Sciences
Exact Sciences Announces First-Quarter 2025 Results
Exact Sciences
Exact Sciences to Highlight Cologuard® Test Adherence and Predicted Preference Data at Digestive Disease Week (DDW) 2025
Exact Sciences
Exact Sciences Launches the Oncodetect™ Molecular Residual Disease Test
Exact Sciences
JAMA Oncology Publication Strengthens Evidence for Oncotype DX® Test Reliability Across Racial and Ethnic Groups
Exact Sciences
Exact Sciences Launches the Cologuard™ Plus Test, Transforming Colorectal Cancer Screening
Exact Sciences
Exact Sciences Named 2025 Gallup Exceptional Workplace Award Winner
Exact Sciences
Exact Sciences Announces Fourth Quarter 2024 Results
Exact Sciences
Flatiron Health and Exact Sciences Partner to Advance Clinical Evidence Generation for Molecular Residual Disease Testing
Exact Sciences
Exact Sciences Demonstrates Leadership in Cancer Innovation with New Data on Screening and Molecular Residual Disease at 2025 ASCO GI Symposium
Exact Sciences
New Evidence Validates Oncodetect’s™ Ability to Detect Molecular Residual Disease and Predict Recurrence in Colorectal Cancer Patients
Exact Sciences
Exact Sciences Announces Preliminary Fourth Quarter 2024 Results
Exact Sciences
Exact Sciences and Lil Jon Partner on “Get Low #2” Campaign to Encourage Colon Cancer Screening
Exact Sciences
Exact Sciences Advances Breast Cancer Care with the Oncotype DX® test and Genomic Profiling Research at SABCS 2024
Exact Sciences
Exact Sciences Partners with Actor and TV Personality Carlos Ponce to Increase Awareness of Colon Cancer Screening Among Hispanic Community
Exact Sciences
Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy
Exact Sciences
Exact Sciences Announces Third-Quarter 2024 Results
Exact Sciences
Exact Sciences Presents Multiple Studies at ACG 2024 Demonstrating Leadership in Noninvasive Colorectal Cancer Screening and Patient Engagement
Exact Sciences
FDA Approves Exact Sciences’ Cologuard Plus™ Test, Setting A New Benchmark in Non-Invasive Colorectal Cancer Screening
Exact Sciences
Exact Sciences Presents Data Demonstrating Advancement in Blood-based Colorectal Cancer Screening at ESMO 2024
Exact Sciences
Exact Sciences Announces First Patient Enrolled in its Multi-Cancer Early Detection (MCED) Falcon Registry Real-World Evidence Study
Exact Sciences
New Modeling Data Show the Cologuard® Test Has Detected More Than 623,000 Cancers and Precancers Over Past Decade, Saving U.S. Health Care System $22 Billion
Exact Sciences
EXACT SCIENCES ANNOUNCES SECOND-QUARTER 2024 RESULTS
Exact Sciences
Exact Sciences Awards Grants to 28 Organizations Focused on Increasing Colorectal Cancer Screening
Exact Sciences
Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations at ASCO®
Exact Sciences
Exact Sciences Earns 2024 Great Place To Work® Certification™
Exact Sciences
Court Ruling Enables Exact Sciences to Proceed with Lawsuit against Geneoscopy
Exact Sciences
Exact Sciences Announces First-Quarter 2024 Results
Exact Sciences
Exact Sciences Demonstrates Continued Scientific Advancement in Colorectal Cancer Screening with Multiple Data Presentations at DDW® 2024
Exact Sciences
Exact Sciences Names Aaron Bloomer as New Chief Financial Officer
Exact Sciences
Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024
Exact Sciences
Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-cancer
Exact Sciences
Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to inform treatment
Exact Sciences
Exact Sciences Named 2024 Gallup Exceptional Workplace Award Winner
Exact Sciences
The New England Journal of Medicine Publishes Cologuard Plus™ Test Results from Pivotal BLUE-C Study
Exact Sciences
Exact Sciences Lab and OncoExTra Test Selected by National Cancer Institute for ComboMATCH Clinical TRIALs
Exact Sciences
Exact Sciences and Basketball Great Jamal Mashburn Encourage Americans 45+ to have a game plan against colon cancer
Exact Sciences
EXACT SCIENCES LAUNCHES RISKGUARD™ HEREDITARY CANCER TEST IN THE UNITED STATES
Exact Sciences
Exact Sciences Announces Fourth Quarter 2023 Results
Exact Sciences
Exact Sciences Announces Preliminary Fourth Quarter 2023 Results
Exact Sciences
DAK PRESCOTT JOINS RYAN REYNOLDS’ MAXIMUM EFFORT AND THE COLORECTAL CANCER ALLIANCE TO 'LEAD FROM BEHIND'
Exact Sciences
Exact Sciences Awards Grants to 23 Organizations Focused on Increasing Colorectal Cancer Screenings
Exact Sciences
Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium Supporting Optimization and individualization of therapy for breast cancer patients
Exact Sciences
Exact Sciences Presents New Long-Term Patient Outcomes In Multi-Cancer Early Detection And Breast Cancer Recurrence Testing at ASCO® 2023
Exact Sciences
Exact Sciences Files Patent Infringement Lawsuit Against Geneoscopy
Exact Sciences
Exact Sciences Announces Third-Quarter 2023 Results
Exact Sciences
Next-Generation Cologuard® Test Demonstrates High Sensitivity and Specificity in Pivotal BLUE-C Study, Significantly outperforming fecal immunochemical testing (FIT) for cancer and precancer detection
Exact Sciences
Exact Sciences Advances Early Cancer Detection and Precision Oncology Programs with Data Presentations at ESMO 2023 Annual Congress
Exact Sciences
Exact Sciences to Present Late-Breaking Data from Pivotal BLUE-C Study on Next-Generation Cologuard at ACG 2023
Exact Sciences
Agilent Technologies and Exact Sciences Agree to Terms of Sale for Resolution Bioscience
Exact Sciences
Not a Wall But an Obstacle Course: New Findings Reveal Why 45-Year-Olds Are Avoiding Colorectal Cancer Screenings
Exact Sciences
Exact Sciences Announces Second-Quarter 2023 Results
Exact Sciences
Exact Sciences Advances Innovative Cancer Technologies and Approaches Through Visionary Collaborations
Exact Sciences
Next Generation Cologuard Test Demonstrates 94 Percent Sensitivity for Colorectal Cancer at 91 Percent specificity, Raising the Bar in Non-invasive Screening
Exact Sciences
Exact Sciences Earns 2023 Great Place To Work® Certification™
Exact Sciences
Exact Sciences Awards Grants To 18 Organizations Focused On Increasing Colorectal Cancer Screenings
Exact Sciences
Exact Sciences Announces First Quarter 2023 Results
Exact Sciences
Exact Sciences Extends Leadership in Colorectal Cancer Screening with New Data Presented at Digestive Disease Week® Annual Meeting
Exact Sciences
EXACT SCIENCES PRESENTS ADVANCEMENTS IN CANCER DETECTION AT AMERICAN ASSOCIATION FOR CANCER RESEARCH® 2023 ANNUAL MEETING
Exact Sciences
Exact Sciences Announces Fourth Quarter 2022 Results
Exact Sciences
Exact Sciences Launches OncoExTra™ Cancer Therapy Selection Test in the U.S.
Exact Sciences
Exact Sciences and PGA Tour Champions Extend Partnership Through 2027
Exact Sciences
Exact Sciences Announces Preliminary Fourth Quarter 2022 Results
Exact Sciences
Medicare and Insurance Policy Updates in 2023 Will Improve Cancer Screening Access by Removing Patient Colonoscopy Cost Following a Positive Cologuard® Test
Exact Sciences
Exact Sciences Awards Grants to Federally Qualified Health Centers Focused on Improving Colorectal Cancer Screening of Vulnerable Populations
Exact Sciences
Exact Sciences Applauds Proposed CMS Change to Colorectal Cancer Screening Policy
Exact Sciences
Updated ASCO Guidelines Strongly Recommend Use of the Oncotype DX Breast Recurrence Score® Test in Node-Negative and the Majority of Node-Positive Early-Stage Breast Cancer Patients
Exact Sciences
Katie Couric and Cologuard Team Up to Spread Awareness and Urgency for People to Get Screened for Colon Cancer
Exact Sciences
Exact Sciences and OncXerna Announce Licensing Agreement to Help Predict Immunotherapy Response for More Patients
Exact Sciences
Exact Sciences Acquires PreventionGenetics to Accelerate Availability of Hereditary Cancer Testing for More Patients
Exact Sciences
Exact Sciences Commits $500,000 to Urban League Black Business Hub
Exact Sciences
Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX® Test
Exact Sciences
Exact Sciences and National Surgical Adjuvant Breast and Bowel Project Announce Clinical Validation Study to Detect Minimal Residual Disease in Colorectal Cancer Patients
Exact Sciences
Exact Sciences Applauds Final Task Force Recommendation That Lowers Starting Age for Colorectal Cancer Screening to 45
Exact Sciences
New NCCN Breast Cancer Guidelines Recognize Oncotype DX Breast Recurrence Score® Test
Exact Sciences
New Data at SABCS 2020 Highlight the Role of the Oncotype DX Breast Recurrence Score® Test in Shaping Clinical Practice
Exact Sciences
RxPONDER Study Results Demonstrate that the Oncotype DX® Test Can Now Spare Chemotherapy Use in the Majority of Women with Node-positive Early-stage Breast Cancer
Exact Sciences
Exact Sciences Mourns the Death of Dr. David Ahlquist, a Pioneer in Early Cancer Detection
Exact Sciences
Exact Sciences Showcases Continued Progress in Cancer Diagnostics at ASCO 2020
Exact Sciences
New Oncotype DX® Real-world Evidence Shows for the First Time the Practice-changing Impact of TAILORx Results
Exact Sciences
Message from Chairman & CEO, Kevin Conroy
Exact Sciences
.png%3Fh%3D1201%26iar%3D0%26w%3D2401%26rev%3D1f36e1248c3e470886fa219bc0a11a93%26hash%3D194AE0F018903E3424F77FAF1C41B5A1&w=3840&q=75)
